CytoArt is a biotechnology company dedicated to advancing the development, quality control, and clinical monitoring of CAR-T cell therapies. By offering our comprehensive anti-idiotypic platform, we are a leading provider of companion diagnostics for CAR-T therapies. We offer accurate and convenient detection products along with technical services and robust global shipping to help our clients ensure the efficacy of their CAR-T therapies.

At CytoArt, we are committed to providing innovative technology. Our anti-idiotypic CAR-T cell detection products offer industry-leading sensitivity in the market, featuring a limit of detection of 0.001% (detecting 1 anti-CD19 CAR-T cell among 100,000 total T cells). Along with exceptional specificity and accuracy towards CAR-T cells, our products provide the best diagnostic solutions for CAR-T therapies.